From the Editors

The Annual Meeting of the American Society of Clinical Oncology (ASCO), held in Chicago each June, brings together more than 40,000 physicians, researchers and other health professionals from over 100 countries to discuss state-of-the-art treatment modalities, new and experimental therapies and ongoing controversies in the field. The largest annual gathering of oncologists in the U.S., the meeting is also attended by scores of dermatologists, educators, members of the press and patient advocates. The attendees frequent lectures, seminars, oral presentations and poster presentations going on 10 or 11 hours a day. In their spare moments, they can explore an exhibitors’ hall stretching over several acres.

This year, The Skin Cancer Foundation’s scientific director and longtime executive editor of The Melanoma Letter, Mark Teich, attended the conference, going to skin cancer sessions on behalf of the Foundation, in hopes of obtaining insights into new and improved strategies on the horizon for melanoma patients. Often enough, his hopes were rewarded. In this issue of The Melanoma Letter, he shares highlights on the present and future of diagnostics and treatment for melanoma and other skin cancers.

Allan C. Halpern, MD • Editor-in-Chief

Ashfaq A. Marghoob, MD • Associate Editor